Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jul 28, 2013; 19(28): 4568-4575
Published online Jul 28, 2013. doi: 10.3748/wjg.v19.i28.4568
Published online Jul 28, 2013. doi: 10.3748/wjg.v19.i28.4568
Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients
Yan-Ying Shen, Ya-Chao Lu, Dan-Ping Shen, Yuan-Jie Liu, Xin-Ying Su, Guan-Shan Zhu, Xiao-Lu Yin, Xing-Zhi Ni, Department of Pathology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
Ya-Chao Lu, Yuan-Jie Liu, Xin-Ying Su, Guan-Shan Zhu, Xiao-Lu Yin, Innovation Center China, Astra Zeneca Global RD, Zhangjiang Hi-Tech Park, Shanghai 201203, China
Dan-Ping Shen, Xing-Zhi Ni, Department of General Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
Author contributions: Zhu GS and Ni XZ designed the study; Shen YY and Shen DP collected all the human material for this work; Shen YY, Lu YC, Liu YJ and Su XY performed the majority of the experiments; Shen YY wrote the manuscript; and Zhu GS and Yin XL revised the manuscript.
Correspondence to: Dr. Xing-Zhi Ni, Department of General Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 1630 Dongfang Road, Shanghai 200127, China. niyin@yahoo.com
Telephone: +86-21-68383711 Fax: +86-21-68383349
Received: January 7, 2013
Revised: March 21, 2013
Accepted: March 28, 2013
Published online: July 28, 2013
Revised: March 21, 2013
Accepted: March 28, 2013
Published online: July 28, 2013
Core Tip
Core tip: This study investigated the contribution of the fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism as a genetic risk factor for gastric cancer (GC) and any associations between this polymorphism and clinicopathological parameters such as age, gender, clinical stage, tumor grade, human epidermal growth factor receptor 2 status and survival. The results suggested that the FGFR4 Gly388Arg polymorphism was not a risk factor for GC cancer initiation but that it was a useful prognostic marker for GC patients when the tumor was relatively small, well differentiated, or at an early clinical stage.